Ipilimumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6859 publications

Olive Oil-Based Lipid Emulsion Ameliorates Immune Checkpoint Inhibitor-Induced Myocarditis via Inhibition of the NF-κB/NLRP3/IL-1β Pathway.

Olive Oil-Based Lipid Emulsion Ameliorates Immune Checkpoint Inhibitor-Induced Myocarditis via Inhibition of the NF-κB/NLRP3/IL-1β Pathway.

Journal: Journal of visualized experiments : JoVE
Published: June 22, 2026

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma.

Journal: CA: a cancer journal for clinicians
Published: June 22, 2026

Flexible Survival Extrapolation with Blended Hazards: Accounting for Treatment Effect Waning in Health Technology Assessment.

Flexible Survival Extrapolation with Blended Hazards: Accounting for Treatment Effect Waning in Health Technology Assessment.

Journal: Medical decision making : an international journal of the Society for Medical Decision Making
Published: June 19, 2026

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

Journal: Blood
Published: June 18, 2026

Development of a Digital Phenotype for Immune-Related Colitis.

Development of a Digital Phenotype for Immune-Related Colitis.

Journal: JCO clinical cancer informatics
Published: June 16, 2026

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026

Methodological considerations in a real-world study of first-line nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Methodological considerations in a real-world study of first-line nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 11, 2026

Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.

Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026

Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers.

Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers.

Journal: Cancer discovery
Published: June 04, 2026

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Journal: Journal for immunotherapy of cancer
Published: June 03, 2026

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2026

Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches.

Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches.

Journal: Immunological medicine
Published: June 02, 2026
Showing 1-12 of 6,859

Last Updated: 06/30/2026